Answers are grounded in this paper and cite their sources.
Sir, CD180 (RP105) is a leucine‐rich repeat (LRR) molecule expressed on the membrane of B‐cells [1, 2]. The molecules bearing LRRs control the recognition of pathogens and the subsequent activation of the immune system [3, 4]. CD180 belongs to the toll‐like receptor family of pathogen receptors. CD180 takes part in B‐cell recognition and lipopolysaccharide signalling [5]. Recent studies have shown decreased CD180 expression on B‐cells in systemic lupus erythematosus (SLE) [6]. The loss of CD180 is associated with B‐cell activation and increased disease activity in SLE patients. We investigated the expression of CD180 on peripheral blood B‐cells in patients with various types of rheumatic disease. Eighty‐six patients with rheumatic diseases, who were receiving prednisolone<15 mg/day, were recruited from our out‐patient clinic. Blood samples were obtained from patients with systemic sclerosis (SSc) (n=21; all females); primary SS (n=18; all females), angiitis syndrome (n=13; 9 males and 4 females), Behçet's disease (n=11; 5 males and 6 females), mixed connective tissue disease (MCTD) (n=10; all females); polymyositis (PM) (n=8; 3 males and 5 females)/dermatomyositis (DM) (n=5; 2 males and 3 females). Thirty‐one healthy controls (12 males and 19 females) were also evaluated.
No takes yet. Share an insight, caveat, or question.
Koarada et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: